Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHReported by Nathan Reiff. Article Published: 2/12/2026. 
In Brief - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than a financial check-up, earnings for companies in the healthcare sector give investors a window into a firm's pipeline and development progress. Even established, stable healthcare firms can surprise with growth after a new blockbuster drug or device, and earnings periods are an opportunity for management to add context beyond FDA notices or approvals. When healthcare companies report earnings on the same day, it can be a busy stretch for investors sorting noteworthy news and planning trades. On Feb. 10, 2026, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors planning next steps. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance U.K.-based pharma giant AstraZeneca closed 2025 by strengthening its position in oncology, which accounted for roughly 44% of product sales in the quarter. Sales of oncology drugs such as Imfinzi and Enhertu rose as much as 48% year over year, helping total revenue increase 8.6% to $58.7 billion for the quarter. After-tax profits rose alongside revenue, climbing to $10.2 billion from $7 billion in the prior-year quarter, and the board declared a second interim dividend 7 cents higher than last year's. Investors also have more to watch as AstraZeneca advances dozens of drugs through clinical trials. Management said 20 Phase 3 readouts are expected in 2026, and the firm forecasts solid gains in both total revenue and core earnings per share (EPS) for full-year 2026. In the hours after its strong earnings release, AZN shares climbed nearly 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, some on Wall Street question the stock's valuation—based on a consensus price target of $95.75, the shares are implied to have roughly a 51% downside from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Watch Earnings and Margins Edwards manufactures replacement heart valves, monitoring systems and other surgical devices. The firm's Q4 2025 results were largely positive, including 13.3% year-over-year sales growth driven by strong transcatheter aortic valve replacement (TAVR) momentum and uptake of the latest SAPIEN valve. However, adjusted EPS missed analysts' estimates, and gross profit margin declined by 0.8 percentage points year over year. Despite the mixed quarter, Edwards remains confident it can meet its prior 2026 outlook, which targeted sales growth of 8% to 10% year over year and EPS of $2.90 to $3.05. EW shares rose about 4% in after-hours trading to trade above $80 following the announcement. About two-thirds of analysts covering EW rate it a Buy, and Wall Street's consensus price target implies roughly 25% upside to $96.77. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, a maker of joint replacement systems and implants, saw its shares rise more than 3% after reporting EPS of $2.42, four cents above consensus, and revenue of $2.2 billion, up almost 11% year over year and slightly ahead of estimates. Strong demand for orthopedic products supported the top- and bottom-line growth. Zimmer is shifting focus toward the U.S., which represents nearly 60% of its business. With insured patients continuing to use more procedures, near-term demand for Zimmer's products is expected to remain healthy. That said, Zimmer faces headwinds from tariffs that could pressure EPS and revenue in 2026, leading management to offer conservative guidance in the latest earnings report, including adjusted EPS of $8.30 to $8.45 and free cash flow growth of 8% to 10%. Before the earnings release, analysts were divided on Zimmer, assigning an overall Hold rating despite about 15% projected upside potential.
| 
